A SORRENTO COMPANY FINDS A CORONAVIRUS ANTIBODY THAT PERFECTLY BLOCKS THE VIRUS INFECTION 100% IN PRECLINICAL TRIAL
US: Emerging report proves that Sorrento company has developed what it claims could potentially be a breakthrough in the treatment of SARS-CoV-2 which is the virus that leads to COVID-19. However, the results emerging from the study are still preclinical study that will still undergo some reviews. The company claimed based on its Friday preclinical research release that it has finally found an antibody that provides “100% inhibition of SARS-CoV-2 virus infection of healthy cells after four days incubation”.
Also, as the subject company continues to push towards the production of an antibody “cocktail” that will potentially prevent SARS-CoV-2 and its family, it’s important to note that Sorrento’s achievement has not been tested on any human, but a laboratory study.
At the moment, there are lots of concerns researchers of SARS-CoV-2 are currently faced with, firstly, is to provide answers regarding how mutagenic SARS-CoV-2 actual nature is, and this is based on the fact that most viruses of this family (coronavirus) similar to the common cold prove to have the tendency to mutate very fast while prolonging cures, and, in turn, making treatment process difficult to handle. Based on this, the laboratory developed antibody by Sorrento implies that it will remain the core antibody in developing other numbers of antibodies that prove efficacious in preventing the attachment of sudden large increase of protein, however, is also aimed at providing multiple protection that is designed to remain effective even in the cases when the virus mutates in an individual body system, or when transmitted from person to person.
To ascertain Sorrento company findings, the company says it believes the antibody it has labeled STI-1499 stood out among billions of antibodies it has been screening from its extensive human antibody library, based on its ability to completely prevent the interaction of the SARS-CoV-2 sudden large increase of protein with human cell aimed receptor. This practically means the antibody prevents the virus from cleaving to the host’s healthy cell that leads to incubation and infection.
In a broader perspective, the primary focus of Sorrento’s COVID-SHIELD is aimed to address this via a strong and effective mix of several antibodies that will practically provide protection against diverse strains of the virus, while in a bid to single-handedly pursue a standalone therapy, the therapeutics company also claimed it is dedicated in the development of the STI-1499 antibody.
Also in a bid to achieve its aim within the time frame that is limited, which it says it is in close communication with regulators about how it could hasting the development of a potential treatment as it pursues FDA’s approval and the goal to ramp up production capacity that will see a million doses at the same time.
Lastly, it’s important to note, there isn’t a treatment or vaccine yet, neither is this a likely treatment of SARS-CoV-2 or COVID-19, yes a promising development but worth cautioning as it undergoes clinical trials.
What is your take as Sorrento Company finds a preventive antibody of the SARS-CoV-2 virus?
Be the first to comment